A Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate

Hoffmann-La Roche582 enrolled

Overview

This observational, multicenter survey is designed to assess the efficacy of oral ibandronate in adults with breast cancer and metastatic bone disease. Data on the use of ibandronate in clinical practice will be collected from Hungarian patients.

Study Type

OBSERVATIONAL

Enrollment

582

Conditions

Metastatic Breast Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults at least 18 years of age * Histologically confirmed breast cancer with bone metastasis * Receiving or indicated for the tablet formulation of ibandronate according to the summary of product characteristics (SmPC) and local labeling Exclusion Criteria: * Contraindication to ibandronate according to SmPC * Ongoing participation in any trial evaluating the efficacy and/or safety of ibandronate

Locations (25)

Unnamed facility

Budapest, Hungary

Unnamed facility

Budapest, Hungary

Unnamed facility

Outcomes

Primary Outcomes

Change in bone pain according to Visual Analog Scale (VAS) score

Time frame: From Baseline to the end of 1 year

Secondary Outcomes

Compliance with tablet formulation of ibandronate according to Case Report Form (CRF) questionnaire

Time frame: Up to approximately 1 year

Incidence of adverse events

Time frame: Up to approximately 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.